SAN DIEGO, June 4, 2019 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, will
participate in two upcoming investor conferences.
- The Goldman Sachs 40th Annual Global Healthcare Conference on
Wednesday, June 12 at 1:40 p.m. ET / 10:40 a.m.
PT in Rancho Palos Verdes,
CA. Dr. Helen Torley,
president and chief executive officer, will represent the company
in a question and answer session.
- The JMP Securities Life Sciences Conference on Wednesday, June 19 at 2:30
p.m. ET / 11:30 a.m. PT in
New York, NY. Laurie Stelzer, senior vice president and chief
financial officer, will represent the company in a question and
answer session.
A live webcast of each session can be accessed through the
"Investors" section of www.halozyme.com, and a recording will be
made available for 90 days following each event. To access a live
webcast, please visit Halozyme's website approximately 15 minutes
prior to the presentation to register and download any necessary
audio software.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program,
investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a
unique approach to targeting solid tumors, allowing increased
access of co-administered cancer drug therapies to the tumor in
animal models. PEGPH20 is currently in development for the
treatment of several cancers and has the potential to be used in
combination with different types of cancer therapies. In addition
to its proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical and
biotechnology companies, including Roche, Baxalta, Pfizer, Janssen,
AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx, for its
ENHANZE® drug delivery technology. Halozyme is
headquartered in San Diego. For
more information visit www.halozyme.com.
Contact:
Al
Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-to-participate-in-upcoming-investor-conferences-300860923.html
SOURCE Halozyme Therapeutics, Inc.